A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With PNH

Trial Profile

A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With PNH

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Biomarker; Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 21 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2020.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Dec 2017 According to an Alexion Pharmaceuticals media release, all patients from the cohorts 1, 2, and 3 of the study have been successfully transitioned to the Phase 3 dosing regimen, after which plasma LDH levels have remained suppressed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top